References
1. O’Mahony, D. et al. STOPP/START criteria for potentially
inappropriate prescribing in older people: version 2. Age Ageing44 , 213–218 (2015).
2. By the 2019 American Geriatrics Society Beers Criteria® Update Expert
Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for
Potentially Inappropriate Medication Use in Older Adults. J. Am.
Geriatr. Soc. 67 , 674–694 (2019).
3. Ancelin, M. L. et al. Non-degenerative mild cognitive
impairment in elderly people and use of anticholinergic drugs:
longitudinal cohort study. BMJ 332 , 455–459 (2006).
4. Fox, C. et al. Anticholinergic Medication Use and Cognitive
Impairment in the Older Population: The Medical Research Council
Cognitive Function and Ageing Study. J Am Geriatr Soc59 , 1477 (2011).
5. Han, L. et al. Use of medications with anticholinergic effect
predicts clinical severity of delirium symptoms in older medical
inpatients. Arch. Intern. Med. 161 , 1099–1105 (2001).
6. Hilmer, S., Mager, D. & Simonsick, E. Drug Burden Index Score and
Functional Decline in Older People. Am J Med 122 , 1142
(2009).
7. Kalisch Ellett, L., Pratt, N. & Ramsay, E. Multiple anticholinergic
medication use and risk of hospital admission for confusion or dementia.J Am Geriatr Soc 62 , 1916 (2014).
8. Koyama, A., Steinman, M., Ensrud, K., Hillier, T. & Yaffe, K.
Long-term Cognitive and Functional Effects of Potentially Inappropriate
Medications in Older Women. J Gerontol Biol Sci Med Sci69 , 423 (2014).
9. Lechevallier-Michel, N., Molimard, M., Dartigues, J., Fabrigoule, C.
& Fourrier-Re´glat, A. Drugs with anticholinergic properties and
cognitive performance in the elderly: results from the PAQUID study.Br J Clin Pharmacol 2005592143-51 59 , 143 (2005).
10. Myint, P., Fox, C. & Kwok, C. Total anticholinergic burden and risk
of mortality and cardiovascular disease over 10 years in 21,636
middle-aged and older men and women of EPIC-Norfolk prospective
population study. Age Ageing 44 , 219 (2015).
11. Ochs, K. L., Zell-Kanter, M., Mycyk, M. B. & Toxikon Consortium.
Hot, blind, and mad: avoidable geriatric anticholinergic delirium.Am. J. Emerg. Med. 30 , 514.e1-514.e3 (2012).
12. Golinger, R., Peet, T. & Tune, L. Association of Elevated Plasma
Anticholinergic activity with delirium in surgical patients. Am J
Psychiatry 144 , 1218 (1987).
13. Mulsant, B. et al. Serum anticholinergic activity in a
community based sample of older adults. Arch Gen Psychiatry60 , 198 (2003).
14. Trenaman, S. Risk Factors For Drug-Related Problems Causing
Emergency Department Visits In Older Adults. (Dalhousie University,
2014).
15. Cabrera, M. A., Dip, R. M., Furlan, M. O. & Rodrigues, S. L. Use of
drugs that act on the cytochrome P450 system in the elderly. Clin.
Sao Paulo Braz. 64 , 273–278 (2009).
16. Buostani, M. Anticholinergic cognitive burden scale. Harvard
Healthhttps://www.health.harvard.edu/newsletter_article/anticholinergic-cognitive-burden-scale
(2009).
17. Goodman, L., Gilman, A., Brunton, L., Lazo, J. & Parker, K.Goodman & Gilman’s the Pharmacological Basis of Therapeutics .
(McGraw-Hill, 2006).
18. Stryer, L. Visual excitation and recovery. J Biol Chem266 , 10711 (1991).
19. Svoboda, P. et al. Biochemistry of Transmembrane Signaling
Mediated by Trimeric G Proteins. Physiol Res 53(Suppl.
1) , S141 (2004).
20. Svoboda, P. & Milligan, G. Agonist-induced transfer of the α
subunits of the guanine-nucleotide-binding regulatory proteins Gq and
G11 and of muscarinic m1 acetylcholine receptors from plasma membranes
to a light-vesicular membrane fraction. Eur J Biochem224 , 455 (1994).
21. Khan, K. M., Drescher, M. J., Hatfield, J. S., Khan, A.-M. &
Drescher, D. G. Muscarinic receptor subtypes are differentially
distributed in the rat cochlea. Neuroscience 111 ,
291–302 (2002).
22. Murthy, K. S. & Makhlouf, G. M. Differential coupling of muscarinic
m2 and m3 receptors to adenylyl cyclases V/VI in smooth muscle.
Concurrent M2-mediated inhibition via Galphai3 and m3-mediated
stimulation via Gbetagammaq. J. Biol. Chem. 272 ,
21317–21324 (1997).
23. Rudolph, J., Salow, M., Angelini, M. & McGlinchey, R. The
anticholinergic risk scale and anticholinergic adverse effects in older
person. Arch Intern Med 168 , 508 (2008).
24. Tune, L., Carr, S., Hoag, E. & Cooper, T. Anticholinergic Effects
of Drugs Commonly Prescribed for the Elderly: Potential Means for
Assessing Risk of Delirium. Am J Psychiatry 149 , 1393
(1992).
25. Buostani, M. Impact of anticholinergics on the aging brain: a review
and practical application. Aging Health 4 , 311 (2008).
26. Carnahan, Lund, B. & Perry, P. The Anticholinergic Drug Scale as a
measure of drug-related anticholinergic burden: associations with serum
anticholinergic activity. J Clin Pharmacol 46 , 1481
(2006).
27. Hilmer, Mager, D. & Simonsick, E. A drug burden index to define the
functional burden of medications in older people. Arch Intern Med167 , 781 (2007).
28. Madsen. Effects of Gender, Age, and Body Mass Index on
Gastrointestinal Transit Times. Dig. Dis. Sci. 37 , 1548
(1992).
29. Madsen & Graff. Effects of ageing on gastrointestinal motor
function. Age Ageing 33 , 154–159 (2004).
30. Bennett, E. J. et al. Psychological and sex features of
delayed gut transit in functional gastrointestinal disorders. Gut46 , 83–87 (2000).
31. Córdova-Fraga, T. et al. Gender difference in the gastric
emptying measured by magnetogastrography using a semi-solid test meal.Acta Gastroenterol Latinoam 38 , 240 (2008).
32. Degen, J. & Phillips, S. Variability of gastrointestinal transit in
healthy women and men. Gut 39 , 299 (1996).
33. Sadik, R., Abrahamsson, H. & Stotzer, P. O. Gender differences in
gut transit shown with a newly developed radiological procedure.Scand. J. Gastroenterol. 38 , 36–42 (2003).
34. Stephen, A. M. et al. The effect of age, sex and level of
intake of dietary fibre from wheat on large-bowel function in thirty
healthy subjects. Br. J. Nutr. 56 , 349–361 (1986).
35. Hutson, W. R., Roehrkasse, R. L. & Wald, A. Influence of gender and
menopause on gastric emptying and motility. Gastroenterology96 , 11–17 (1989).
36. Grossman, M., Kirsner, J. & Gillespie, I. Basal and
histalogstimulated gastric secretion in control subjects and in patients
with peptic ulcer or gastric cancer. Gastroenterology45 , 14 (1963).
37. Feldman, M. & Barnett, C. Fasting gastric pH and its relationship
to true hypochlorhydria in humans. Dig. Dis. Sci. 36 ,
866–869 (1991).
38. Lindahl, A., Ungell, A. L., Knutson, L. & Lennernas, H.
Characterization of fluids from the stomach and proximal jejunum in men
and women. Pharm. Res. 14 , 497–502 (1997).
39. Perez de la Cruz Moreno, M. et al. Characterization of
fasted-state human intestinal fluids collected from duodenum and
jejunum. J. Pharm. Pharmacol. 58 , 1079–1089 (2006).
40. Gorski, J., Jones, D. & Haehner-Daniels, B. The contribution of
intestinal and hepatic CYP3A to the interaction between midazolam and
clarithromycin. Clin Pharmacol Ther 64 , 133 (1998).
41. Kates, R., Keefe, D. & Schwartz, J. Verapamil disposition kinetics
in chronic atrial fibrillation. Clin Pharmacol Ther 30 ,
44 (1981).
42. Krecic-Shepard, Barnas, C. & Slimko, J. Gender-specific effects on
verapamil pharmacokinetics and pharmacodynamics in humans. J Clin
Pharmacol 40 , 219 (2000).
43. Paine, M., Ludington, S. & Chen, M. Do men and women differ in
proximal small intestinal cyp3a or P-glycoprotein expression? Drug
Metab Dispos 33 , 426 (2005).
44. Krecic-Shepard, C. R. Barnas & Slimko, J. Faster clearance of
sustained release verapamil in men versus women: continuing observations
on sex-specific differences after oral administration of verapamil.Clin. Pharmacol. Ther. 68 , 286–292 (2000).
45. López-Ortega, M. & Arroyo, P. Anthropometric characteristics and
body composition in Mexican older adults: age and sex differences.Br J Nutr 115 , 490 (2016).
46. Schwartz, J. The Influence of sex on Pharmacokinetics. Clin
Pharmacokinet 42 , 107 (2003).
47. Pakulski, C., Drobnik, L. & Millo, B. Age and sex as factors
modifying the function of the blood-cerebrospinal fluid barrier.Med Sci Monit 6 , 314 (2000).
48. Roberts, D. J. & Goralski, K. B. A critical overview of the
influence of inflammation and infection on P-glycoprotein expression and
activity in the brain. Expert Opin. Drug Metab. Toxicol.4 , 1245–1264 (2008).
49. Parkinson, A., Mudra, D., Johnson, C., Dwyer, A. & Carroll, K. The
effects of gender, age, ethnicity, and liver cirrhosis on cytochrome
P450 enzyme activity in human liver microsomes and inducibility in
cultured human hepatocytes. Toxicol. Appl. Pharmacol.199 , 193 (2004).
50. Greenblatt, D. J., Divoll, M., Harmatz, J. S. & Shader, R. I.
Oxazepam kinetics: effects of age and sex. J. Pharmacol. Exp.
Ther. 215 , 86–91 (1980).
51. Wolbold, R. et al. Sex is a major determinant of CYP3A4
expression in human liver. Hepatol. Baltim. Md 38 ,
978–988 (2003).
52. George, J., Byth, K. & Farrell, G. Age but not gender selectively
affects expression of individual cytochrome P450 proteins in human
liver. Biochem Pharmacol 50 , 727 (1995).
53. Schmucker, D. L. et al. Effects of age and gender on in vitro
properties of human liver microsomal monooxygenases. Clin.
Pharmacol. Ther. 48 , 365–374 (1990).
54. Hunt, C., Westerkam, W. & Stave, G. Effect of age and gender on the
activity of human hepatic CYP3A. Biochem Pharmacol 44 ,
275 (1992).
55. Krecic-Shepard, M. E. et al. Race and sex influence clearance
of nifedipine: results of a population study. Clin. Pharmacol.
Ther. 68 , 130–142 (2000).
56. Greenblatt, D. J., Allen, M. D., Harmatz, J. S. & Shader, R. I.
Diazepam disposition determinants. Clin. Pharmacol. Ther.27 , 301–312 (1980).
57. Greenblatt, D. J. & von Moltke, L. L. Gender has a small but
statistically significant effect on clearance of CYP3A substrate drugs.J. Clin. Pharmacol. 48 , 1350–1355 (2008).
58. Hu, Z. Y. & Zhao, Y. S. Sex-dependent differences in cytochrome
P450 3A activity as assessed by midazolam disposition in humans: a
meta-analysis. Drug Metab. Dispos. Biol. Fate Chem. 38 ,
817–823 (2010).
59. del Carmen Carrasco-Portugal, M., Lujan, M. & Flores-Murrieta, F.
J. Evaluation of gender in the oral pharmacokinetics of clindamycin in
humans. Biopharm. Drug Dispos. 29 , 427–430 (2008).
60. Bebia, Z. et al. Bioequivalence revisited: influence of age
and sex on CYP enzymes. Clin. Pharmacol. Ther. 76 ,
618–627 (2004).
61. Okada, Y. et al. Population Estimation Regarding the Effects
of Cytochrome P450 2C19 and 3A5 Polymorphisms on Zonisamide Clearance:Ther. Drug Monit. PAP , (2008).
62. Sinues, B. et al. CYP2A6 activity in a healthy Spanish
population: effect of age, sex, smoking, and oral contraceptives.Hum. Exp. Toxicol. 27 , 367–372 (2008).
63. Bock, K. W. et al. The influence of environmental and genetic
factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using
sparteine, caffeine, and paracetamol as probes. Pharmacogenetics4 , 209–218 (1994).
64. Court, M. H. et al. Interindividual variability in
acetaminophen glucuronidation by human liver microsomes: identification
of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J.
Pharmacol. Exp. Ther. 299 , 998–1006 (2001).
65. Pacifici, G. M., Evangelisti, L., Giuliani, L., Metelli, R. M. &
Giordani, R. Zidovudine glucuronidation in human liver: interindividual
variability. Int. J. Clin. Pharmacol. Ther. 34 , 329–334
(1996).
66. Divoll, M., Greenblatt, D. J., Harmatz, J. S. & Shader, R. I.
Effect of age and gender on disposition of temazepam. J. Pharm.
Sci. 70 , 1104–1107 (1981).
67. Miners, J. O., Attwood, J. & Birkett, D. J. Influence of sex and
oral contraceptive steroids on paracetamol metabolism. Br. J.
Clin. Pharmacol. 16 , 503–509 (1983).
68. Boudikova, B., Szumlanski, C., Maidak, B. & Weinshilboum, R. Human
liver catechol-O-methyltransferase pharmacogenetics. Clin.
Pharmacol. Ther. 48 , 381–389 (1990).
69. Schuetz, E., Furuya, K. & Schuetz, J. Interindividual variation in
expression of P-glycoprotein in normal human liver and secondary hepatic
neoplasms. J Pharmacol Exp Ther 275 , 1011 (1995).
70. Godfrey, C., Sweeney, K., Miller, K., Hamilton, R. & Kremer, J. The
population pharmacokinetics of long-term methotrexate in rheumatoid
arthritis. Br. J. Clin. Pharmacol. 46 , 369–376 (1998).
71. Franconi, F., Brunelleschi, S., Steardo, L. & Cuomo, V. Gender
differences in drug responses. Pharmacol. Res. 55 ,
81–95 (2007).
72. Yukawa, E., Mine, H. & Higuchi, S. Digoxin population
pharmacokinetics from routine clinical data: role of patient
characteristics for estimating dosing regimens. . 1992;44: 761-765.J Pharm Pharmacol 44 , 761 (1992).
73. Gaudry, S. E., Sitar, D. S., Smyth, D. D., McKenzie, J. K. & Aoki,
F. Y. Gender and age as factors in the inhibition of renal clearance of
amantadine by quinine and quinidine. Clin. Pharmacol. Ther.54 , 23–27 (1993).
74. Benton, R., Sale, M., Flockhart, D. & Woosley, R. Greater quinidine
induced QTc interval prolongation in women. Clin Pharmacol Ther67 , 413 (2000).
75. El-Eraky, H. & Thomas, S. Effects of sex on the pharmacokinetic and
pharmacodynamics properties of quinidine. Br J Clin Pharmacol56 , 198 (2003).
76. Vicente, J. et al. Investigation of potential mechanisms of
sex differences in quinidine-induced torsade de pointes risk. J.
Electrocardiol. 48 , 533 (2015).
77. Winchell, G., King, J., Chavez-Eng, C., Constanzer, M. & Korn, S.
Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender,
and Hepatic Insufficiency. J. Clin. Pharmacol. 42 , 61
(2002).
78. MacLeod, S. M., Giles, H. G., Bengert, B., Liu, F. F. & Sellers, E.
M. Age- and gender-related differences in diazepam pharmacokinetics.J. Clin. Pharmacol. 19 , 15–19 (1979).
79. Bigos, K. L. et al. Sex, race, and smoking impact olanzapine
exposure. J. Clin. Pharmacol. 48 , 157–165 (2008).
80. Waade, R. B., Molden, E., Refsum, H. & Hermann, M. Serum
concentrations of antidepressants in the elderly. Ther. Drug
Monit. 34 , 25–30 (2012).
81. Mundo, E., Pirola, R., Bellodi, L., Smeraldi, E. & Bareggi, S. R.
Are gender differences in antiobsessional response related to different
clomipramine metabolism? J. Clin. Psychopharmacol. 22 ,
341–342 (2002).
82. Unterecker, S. et al. Effects of gender and age on serum
concentrations of antidepressants under naturalistic conditions.J. Neural Transm. Vienna Austria 1996 120 , 1237–1246
(2013).
83. Reis, M., Aamo, T., Spigset, O. & Ahlner, J. Serum concentrations
of antidepressant drugs in a naturalistic setting: compilation based on
a large therapeutic drug monitoring database. Ther. Drug Monit.31 , 42–56 (2009).
84. Hartter, S., Wetzel, H., Hammes, E., Torkzadeh, M. & Hiemke, C.
Nonlinear pharmacokinetics of fluvoxamine and gender differences.Ther. Drug Monit. 20 , 446–449 (1998).
85. Feng, Y. et al. Paroxetine: population pharmacokinetic
analysis in late-life depression using sparse concentration sampling.Br. J. Clin. Pharmacol. 61 , 558–569 (2006).
86. Gex-Fabry, M. et al. CYP2D6 and ABCB1 genetic variability:
influence on paroxetine plasma level and therapeutic response.Ther. Drug Monit. 30 , 474–482 (2008).
87. Findlay, J. W. et al. Pharmacokinetics of bupropion, a novel
antidepressant agent, following oral administration to healthy subjects.Eur. J. Clin. Pharmacol. 21 , 127–135 (1981).
88. Sweet, R. A. et al. Pharmacokinetics of single- and
multiple-dose bupropion in elderly patients with depression. J.
Clin. Pharmacol. 35 , 876–884 (1995).
89. Preskorn, S. H. & Mac, D. S. Plasma levels of amitriptyline: effect
of age and sex. J. Clin. Psychiatry 46 , 276–277 (1985).
90. Dahl, M. L., Bertilsson, L. & Nordin, C. Steady-state plasma levels
of nortriptyline and its 10-hydroxy metabolite: relationship to the
CYP2D6 genotype. Psychopharmacology (Berl.) 123 ,
315–319 (1996).
91. Abernethy, D. R., Greenblatt, D. J. & Shader, R. I. Imipramine and
desipramine disposition in the elderly. J. Pharmacol. Exp. Ther.232 , 183–188 (1985).
92. Aichhorn, W., Weiss, U. & Marksteiner, J. Influence of age and
gender on risperidone plasma concentrations. J Psychopharmacol19 , 395 (2005).
93. McCune, J., Lindley, C. & Decker, J. Lack of gender differences and
large intrasubject variability in cytochrome P450 activity measured by
phenotyping with dextromethorphan. J Clin Pharmacol 41 ,
723 (2001).
94. Rademaker, M. Do women have more adverse drug reactions? Am.
J. Clin. Dermatol. 2 , 349–351 (2001).
95. Watson, S., Caster, O., Rochon, P. A. & Ruijter, H. den. Reported
adverse drug reactions in women and men: Aggregated evidence from
globally collected individual case reports during half a century.EClinicalMedicine 17 , (2019).
96. Lukkari, E., Hakonen, T. & Neuvonen, P. J. The pharmacokinetics of
oxybutynin is unaffected by gender and contraceptive steroids.Eur. J. Clin. Pharmacol. 53 , 351–354 (1998).
97. Malhotra, B., Wood, N. & Sachse, R. Influence of age gender and
race on pharmacokinetics, pharmacodynamics and safety of fesoterodine.Int. J. Clin. Pharmacol. Ther. 47 , 570 (2009).
98. Kerbusch, T., Wahlby, U., Milligan, P. A. & Karlsson, M. O.
Population pharmacokinetic modelling of darifenacin and its hydroxylated
metabolite using pooled data, incorporating saturable first-pass
metabolism, CYP2D6 genotype and formulation-dependent bioavailability.Br. J. Clin. Pharmacol. 56 , 639–652 (2003).
99. Doroshyenko, O. & Fuhr, U. Clinical pharmacokinetics and
pharmacodynamics of solifenacin. Clin. Pharmacokinet.48 , 281–302 (2009).
100. Diefenbach, K. et al. Randomised, double-blind study of the
effects of oxybutynin, tolterodine, trospium chloride and placebo on
sleep in healthy young volunteers. Clin. Drug Investig.23 , 395–404 (2003).
101. Koren, G., Vranderick, M., Gill, S. & Macleod, S. Combination of
Doxylamine Succinate‐Pyridoxine Hydrochloride; Implications for
Pharmacotherapy in Pregnancy. J. Clin. Pharmacol. 53 ,
1268 (2013).
102. Ebert, U., Oertel, R. & Kirch, W. Influence of grapefruit juice on
scopolamine pharmacokinetics and pharmacodynamics in healthy male and
female subjects. Int. J. Clin. Pharmacol. Ther. 38 ,
523–531 (2000).
103. Sotaniemi, E. A., Arranto, A. J., Pelkonen, O. & Pasanen, M. Age
and cytochrome P450-linked drug metabolism in humans: an analysis of 226
subjects with equal histopathologic conditions. Clin. Pharmacol.
Ther. 61 , 331–339 (1997).
104. Greenblatt, D. J., Harmatz, J. S., von Moltke, L. L., Wright, C. E.
& Shader, R. I. Age and gender effects on the pharmacokinetics and
pharmacodynamics of triazolam, a cytochrome P450 3A substrate.Clin. Pharmacol. Ther. 76 , 467–479 (2004).
105. Court, M. H. Interindividual variability in hepatic drug
glucuronidation: studies into the role of age, sex, enzyme inducers, and
genetic polymorphism using the human liver bank as a model system.Drug Metab. Rev. 42 , 209–224 (2010).
106. Wynne, H. A. et al. The association of age and frailty with
paracetamol conjugation in man. Age Ageing 19 , 419–424
(1990).
107. Wynne, H. A. et al. The association of age and frailty with
the pharmacokinetics and pharmacodynamics of metoclopramide. Age
Ageing 22 , 354–359 (1993).
108. Hilmer, S. N. et al. Age-related changes in the hepatic
sinusoidal endothelium impede lipoprotein transfer in the rat.Hepatol. Baltim. Md 42 , 1349–1354 (2005).
109. Le Couteur, D. G., Fraser, R., Hilmer, S., Rivory, L. P. & McLean,
A. J. The hepatic sinusoid in aging and cirrhosis: effects on hepatic
substrate disposition and drug clearance. Clin. Pharmacokinet.44 , 187–200 (2005).
110. Le Couteur, D. G. et al. Pseudocapillarization and
associated energy limitation in the aged rat liver. Hepatol.
Baltim. Md 33 , 537–543 (2001).
111. Hilmer, S. N., Cogger, V. C., Muller, M. & Le Couteur, D. G. The
hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin.Drug Metab. Dispos. Biol. Fate Chem. 32 , 794–799
(2004).
112. Cockcroft, D. & Gault, M. Prediction of creatinine clearance from
serum creatinine. Nephron 16 , 31 (1976).
113. Isah, A., Rawlins, M. & Bateman, D. The Pharmacokinetics and
Effects of Prochlorperazine in Elderly Female Volunteers. Age
Aging 21 , 27 (1992).
114. van Assema, D. et al. P-Glycoprotein Function at the
Blood–Brain Barrier: Effects of Age and Gender. Mol Imaging Biol14 , 771 (2012).
115. Tamminga, W. & Ossterhuis, B. CYP2D6 and CYP 2C19 activity in a
large population of Dutch healthy volunteers: indications for oral
contraceptive-related gender differences. Eur J CLin Pharmacol55 , 177 (1999).
116. Dawling, S. Monitoring of tricyclic antidepressant therapy.Clin. Biochem. 15 , 56–61 (1982).
117. Sawamura, K., Suzuki, Y. & Someya, T. Effects of dosage and
CYP2D6-mutated allele on plasma concentration of paroxetine. Eur.
J. Clin. Pharmacol. 60 , 553–557 (2004).
118. Goodnick, P. J. Pharmacokinetics of second generation
antidepressants: bupropion. Psychopharmacol. Bull. 27 ,
513–519 (1991).
119. Hughes, K. M. et al. Measurement of oxybutynin and its
N-desethyl metabolite in plasma, and its application to pharmacokinetic
studies in young, elderly and frail elderly volunteers.Xenobiotica Fate Foreign Compd. Biol. Syst. 22 , 859–869
(1992).
120. Alvarez-Jimenez, R. et al. Model-based exposure-response
analysis to quantify age related differences in the response to
scopolamine in healthy subjects. Br. J. Clin. Pharmacol.82 , 1011–1021 (2016).
121. Lopes, G. S. et al. Sex Differences in Associations Between
CYP2D6 Phenotypes and Response to Opioid Analgesics.Pharmacogenomics Pers. Med. 13 , 71–79 (2020).
122. Kersten, H., Wyller, T. & Molden, E. Association Between Inherited
CYP2D6/2C19 Phenotypes and Anticholinergic Measures in Elderly Patients
Using Anticholinergic Drugs. Ther Drug Monit 36 , 125
(2014).
123. Vandenberghe, F. et al. Genetics-Based Population
Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric
Cohort. Clin. Pharmacokinet. 54 , 1259–1272 (2015).
124. Cabaleiro, T. et al. Polymorphisms in CYP2D6 have a greater
effect on variability of risperidone pharmacokinetics than gender.Basic Clin. Pharmacol. Toxicol. 116 , 124–128 (2015).
125. Brynne, N. et al. Pharmacokinetics and pharmacodynamics of
tolterodine in man: a new drug for the treatment of urinary bladder
overactivity. Int. J. Clin. Pharmacol. Ther. 35 ,
287–295 (1997).
126. Byeon, J.-Y. et al. Influence of CYP2D6 genetic polymorphism
on pharmacokinetics of active moiety of tolterodine. Arch. Pharm.
Res. 42 , 182–190 (2019).
127. Brynne, N., Dalén, P., Alván, G., Bertilsson, L. & Gabrielsson, J.
Influence of CYP2D6 polymorphism on the pharmacokinetics and
pharmacodynamic of tolterodine. Clin. Pharmacol. Ther.63 , 529–539 (1998).
128. Patel, N., Wisniowska, B. & Polak, S. Virtual Thorough QT (TQT)
Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation
Using Multi-Scale Physiologically Based Ventricular Cell-wall Model
Exemplified with Tolterodine and Fesoterodine. AAPS J.20 , 83 (2018).
129. Nilvebrant, L., Hallén, B. & Larsson, G. Tolterodine–a new
bladder selective muscarinic receptor antagonist: preclinical
pharmacological and clinical data. Life Sci. 60 ,
1129–1136 (1997).
130. Beaumont, K. C., Cussans, N. J., Nichols, D. J. & Smith, D. A.
Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog
and man. Xenobiotica Fate Foreign Compd. Biol. Syst. 28 ,
63–75 (1998).
131. Jürgens, G. et al. Does the medication pattern reflect the
CYP2D6 genotype in patients with diagnoses within the schizophrenic
spectrum? J. Clin. Psychopharmacol. 32 , 100–105 (2012).
132. Chew, M., Mulsant, B. & Pollock, B. Serum Anticholinergic Activity
and Cognition in Patients with Moderate-to-Severe Dementia. Am J
Geriatr Psychiatry 13 , 535 (2005).
133. Haab, F. et al. Long-term treatment with darifenacin for
overactive bladder: results of a 2-year, open-label extension study.BJU Int. 98 , 1025 (2006).
134. Geller, E. J. et al. Effect of anticholinergic use for the
treatment of overactive bladder on cognitive function in postmenopausal
women. Clin. Drug Investig. 32 , 697–705 (2012).
135. Hill, S. et al. Long-term darifenacin treatment for
overactive bladder in patients aged 65 years and older: analysis of
results from a 2-year, open-label extension study. Curr. Med. Res.
Opin. 23 , 2697–2704 (2007).
136. Armstrong, R. B., Dmochowski, R. R., Sand, P. K. & Macdiarmid, S.
Safety and tolerability of extended-release oxybutynin once daily in
urinary incontinence: combined results from two phase 4 controlled
clinical trials. Int. Urol. Nephrol. 39 , 1069–1077
(2007).
Table 1: Studies that have investigated the risk of serious adverse drug
events and mortality related to the use of anticholinergic drugs in
older adults